CAR macrophage tumor tech created by UPenn star scientists gets $53M
A couple of star scientists at UPenn just got financial backing from AbbVie and other investors to come at solid tumors in an unusual way: re-engineering macrophages to eat up cancer cells.
The Philadelphia-based company was first christened “Carma Therapeutics” when it launched last year, but thanks to pesky trademark conflicts its stepping out today with a new moniker: Carisma Therapeutics. And the new name comes with $53 million in a Series A round led by AbbVie Ventures and HealthCap.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
